Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Latest Trials

Systemic therapy trial

ORIENT-15 : A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy...

This phase III trial is tying to understand how safe and effective a targeted therapy is for the treatment of advanced oesophageal squamous cell carcinoma, when given in combination with chemotherapy

Status : Recruiting

Systemic therapy trial

IMPARP-HRD : An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination...

This phase II study is evaluating how effective a combined treatment of two targeted therapies (pamiparib and tislelizumab) in people with advanced cancers that have molecular profiles consistent with homologous recombination deficiency (HRD)

Status : Recruiting

Systemic therapy trial

CYCLONE 3 : CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib...

This phase III study is trying to determine whether adding targeted therapy (abemaciclib) to hormone therapy (abiraterone) in combination with steroids (prednisolone or prednisone) prolongs the time before prostate cancer gets worse

Status : Recruiting

Systemic therapy trial

MK-6482-022 : A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety...

This phase III study is evaluating how safe and effective an oral cancer drug (belzutifan), compared with a placebo, is in combination with immunotherapy (pembrolizumab) in people with kidney cancer who have had surgery

Status : Recruiting

Systemic therapy trial

ENHANCE-2 : A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab...

This phase III trial is comparing the effectiveness of three different treatments in people with previously untreated, TP53 mutant, acute myeloid leukaemia: a new targeted therapy (magrolimab) combined with a hypomethylating agent which reduces the number of abnormal blood cells (azacitidine); a different targeted therapy (venetoclax) combined with the hypomethylating agent (azacitidine); and an intensive chemotherapy regimen (including cytarabine, and daunorubicin or idarubicin)

Status : Recruiting

Systemic therapy trial

EVOKE-01 : Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan...

This phase III trial is trying to determine whether targeted therapy (Sacituzumab Govitecan-hziy) is more effective than chemotherapy (Docetaxel) in people with advanced or metastatic non-small cell lung cancer who have had previous treatment

Status : Recruiting

Systemic therapy trial

ACE-Breast03 : A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients...

This Phase II trial is trying to understand the effectiveness of a new targeted therapy (ARX788) in people with HER2-positive metastatic breast cancer who have not responded to other targeted therapies (T-DM1, T-DXd, Tucatinib)

Status : Recruiting

Systemic therapy trial

lidERA Breast Cancer : A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety...

This phase III trial is comparing the safety and effectiveness of a hormone therapy drug called Giredestrant with other types of hormone therapy for the treatment of stage 1-3 ER positive and HER2 negative breast cancer

Status : Recruiting

Radiotherapy trial

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab)...

This phase III study is evaluating whether immunotherapy (pembrolizumab/vibostolimab) in combination with chemoradiotherapy followed by further treatment with immunotherapy is more effective than treatment with chemoradiotherapy followed by a different type of immunotherapy (durvalumab), in people with non-small cell lung cancer

Status : Recruiting

Systemic therapy trial

TIGIT : Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of...

This phase 1 trial is examining the safety and effectiveness of two targeted therapies (BGB-A1217 and Tislelizumab) for the treatment of advanced solid tumours

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.